国产熊去氧胆酸治疗原发性胆汁性肝硬化患者的随访

被引：12

作者：

高峰

张福奎

贾继东

机构：

[1] 首都医科大学附属北京友谊医院肝病中心

来源：

临床肝胆病杂志 | 2008年 / 04期

关键词：

熊去氧胆酸; 原发性胆汁性肝硬化; 治疗;

D O I：

暂无

中图分类号：

R575.22 [];

学科分类号：

摘要：

目的观察国产熊去氧胆酸对原发性胆汁性肝硬化患者肝功生化指标的影响。方法选择北京友谊医院经肝穿活检病理学或AMA-M2阳性而确诊的原发性胆汁性肝硬化患者,应用国产熊去氧胆酸(13-15)mg/kg day,分三次口服,定期(每隔3个月)复查肝功。结果从用药第三个月起,γ-GT、ALP、ALT、AST水平开始明显下降(P<0.05)。结论国产熊去氧胆酸可以改善原发性胆汁性肝硬化患者胆汁淤积相关指标(GGT、ALP),降低转氨酶(ALT、AST)水平。

引用

收藏

页码：278 / 280

页数：3

相关论文

共 14 条

[1]

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis [J].

Poupon, RE ;

Lindor, KD ;

Parés, A ;

Chazouillères, O ;

Poupon, R ;

Heathcote, EJ .

JOURNAL OF HEPATOLOGY, 2003, 39 (01) :12-16

[2]

Ursodeoxycholic acid for primary biliary cirrhosis: Final results of a 12-year, prospective, randomized, controlled trial [J].

Papatheodoridis, GV ;

Hadziyannis, ES ;

Deutsch, M ;

Hadziyannis, SJ .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (08) :2063-2070

[3]

Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha [J].

Alpini, G ;

Baiocchi, L ;

Glaser, S ;

Ueno, Y ;

Marzioni, M ;

Francis, H ;

Phinizy, JL ;

Angelico, M ;

LeSage, G .

HEPATOLOGY, 2002, 35 (05) :1041-1052

[4]

Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited [J].

Paumgartner, G ;

Beuers, U .

HEPATOLOGY, 2002, 36 (03) :525-531

[5]

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes [J].

Qiao, L ;

Yacoub, A ;

Studer, E ;

Gupta, S ;

Pei, XY ;

Grant, S ;

Hylemon, PB ;

Dent, P .

HEPATOLOGY, 2002, 35 (04) :779-789

[6]

Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients [J].

Corpechot, C ;

Carrat, F ;

Poupon, R ;

Poupon, RE .

GASTROENTEROLOGY, 2002, 122 (03) :652-658

[7]

The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent [J].

Rodrigues, CMP ;

Steer, CJ .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (07) :1243-1253

[8]

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders' [J].

Lazaridis, KN ;

Gores, GJ ;

Lindor, KD .

JOURNAL OF HEPATOLOGY, 2001, 35 (01) :134-146

[9]

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis [J].

Goulis, J ;

Leandro, G ;

Burroughs, AK .

LANCET, 1999, 354 (9184) :1053-1060

[10]

Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes [J].

Benz, C ;

Angermüller, S ;

Töx, U ;

Klöters-Plachky, P ;

Riedel, HD ;

Sauer, P ;

Stremmel, W ;

Stiehl, A .

JOURNAL OF HEPATOLOGY, 1998, 28 (01) :99-106